Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319772 | 0.93 | KDM4E (0.49) | HTR6PTGS1PTGS2ALDH1A1GAA | |
| SCHEMBL14688661 | 0.84 | KDM4E (0.46) | HTR6PTGS1PTGS2ALDH1A1GAA | |
| SCHEMBL2360724 | 0.83 | HTR6 (0.47) | HTR6PTGS1PTGS2ALDH1A1GAA | |
| SCHEMBL2359552 | 0.82 | HTR6 (0.46) | HTR6PTGS1PTGS2ALDH1A1GAA | |
| SCHEMBL2360445 | 0.82 | HTR6 (0.42) | HTR6PTGS1PTGS2ALDH1A1GAA | |
| SCHEMBL14688409 | 0.82 | ALDH1A1 (0.40) | HTR6ALDH1A1GAASMN1; SMN2MAPT | |
| SCHEMBL2359516 | 0.75 | PTGS1 (0.44) | HTR6PTGS1PTGS2ALDH1A1GAA | |
| SCHEMBL2359637 | 0.75 | MAPT (0.41) | HTR6PTGS1PTGS2ALDH1A1GAA | |
| SCHEMBL2358271 | 0.74 | PTGS1 (0.43) | HTR6PTGS1PTGS2ALDH1A1GAA | |
| SCHEMBL2358234 | 0.73 | KDM4E (0.48) | HTR6PTGS1PTGS2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2531029-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
| EP-2531029-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | Radius Health, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097496-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121285-A1 | Selective androgen receptor modulators | AR, SHBG, FSHR | HTR6 544/4885PTGS1 920/4885PTGS2 563/4885 |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, FSHR | HTR6 526/4885PTGS1 919/4885PTGS2 561/4885 |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | AR, SHBG, GPR119 | HTR6 683/4885PTGS1 1085/4885PTGS2 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.